In the ever-growing market of oncology, the lengthy drug development process is to be challenged to optimise the time to demonstrate the safety and efficacy of innovative cancer therapies. We provide expertise from the pre-clinical stage through to regulatory marketing approval. With global experience working on many cancer indications using numerous product types, Artemida Pharma has an in-depth knowledge of cancer drug development.
Artemida Pharma has led more than 53 Oncology Advisory Boards covering a broad number of therapeutic modalities including therapeutic/device combinations in solid and haematological cancers and provided over 50 oncology development plans.
| Class/Product Type | No. projects | Territory* |
|---|---|---|
| Acoustic Cluster Therapy | 1 | EU |
| Antibody-dependent cellular cytotoxic | 1 | US/EU |
| Anticancer vaccines | 6 | US/EU/J |
| Anti-metabolite | 3 | US/EU/J |
| Ataxia-telangiectasia mutated (ATM) Inhibitor | 1 | EU |
| Cell-Cycle Inhibitors | 1 | J |
| C-Met inhibitor | 1 | US |
| Hormonal | 1 | EU |
| Immunotherapy | 3 | US/EU/J |
| Matrix mettaloprotease inhibitor | 1 | US/EU |
| Monoclonal Antibodies | 3 | J |
| Palliative Co-therapies | 3 | J |
| Platinum Analogues | 5 | US/EU/J |
| P-Selectin | 1 | EU |
| Photodynamic therapy | 3 | EU/US/Mexico |
| Radiopharmaceuticals | 3 | Australia/USA |
| RAS peptide vaccine | 2 | EU/Australia/New Zealand |
| Tyrosine kinase Inhibitors | 3 | US/EU/J |
| TLR2 Mab | 1 | US/EU |
| TLR7 agonist | 1 | US/EU |
| Topoisomerase Inhibitors | 3 | US/EU |
| Vascular targeting | 3 | US/EU/J |
Besides strategic planning, Artemida Pharma has provided services with regard to the conduct of these programmes including project management, regulatory support, medical support (including medical monitoring) pharmacovigilance, etc.
The high prevalence and lifelong nature of inflammatory and autoimmune diseases create the potential for novel drugs to have a high impact. Our team has a wealth of experience in developmental plans and programmes in the field and will use their expertise to guide you through the process.
| Type | Experience |
|---|---|
| Circulatory | atherosclerosis |
| Dermatology | psoriasis |
| Gastroenterology | ulcerative colitis, Crohn’s Disease |
| Hepatic | non-alcoholic steatohepatitis (NASH) |
| Neurological | multiple sclerosis |
| Renal | acute kidney injury, glomerulonephritis, post renal transplant reperfusion injury |
| Respiratory | asthma, allergic rhinitis |
| Rheumatology | rheumatoid arthritis, osteoarthritis scleroderma |
| Other | shock & burns, inflammatory pain, ischaemic reperfusion injury |
Artemida Pharma has extensive expertise in drug development for bacterial, viral and parasitic infections. We are particularly proud of our work in neglected tropical diseases, including African trypanosomiasis, leishmaniasis and malaria. Through collaboration with a public private partnership and a pharmaceutical company for nearly 20 years, we have taken a malaria drug along the developmental pipeline from non-clinical development to registration for children and adults.
| Type of infection | Experience |
|---|---|
| Parasitic |
African trypanosomiasis
leishmaniasis malaria (Plasmodium species) |
| Bacterial |
severe sepsis
Traveller’s diarrhoea (Campylobacter jejuni) vaccine |
| Viral |
Covid-19 vaccine and treatment
influenza |
The limited understanding of disease pathophysiology, unclear clinical endpoints and long nature of the process can make the neuroscience drug development process challenging. Our breadth of experience will help you navigate and overcome these challenges:
| Type of disease | Experience |
|---|---|
| Neurological |
Alzheimer’s disease
Huntingdon Disease Parkinson’s Disease |
| Pain/Neuropathy |
acute pain
neuropathic pain cancer induced peripheral neuropathy (CIPN) |
| Psychiatric | schizophrenia |
Rapid cardiovascular technology innovation, including increases in cardiovascular drug discovery and the development of devices such as stents, is anticipated to help address the unmet clinical needs of cardiovascular disease patients. Through our experience with congestive heart failure, hypertension, stroke, and vascular occlusion, we can guide you effectively through this changing development landscape.
| Cardiovascular disease | Product Type |
|---|---|
| Congestive heart failure |
glial growth factor 2 (GGF2)
ACE Inhibitor |
| Hypertension |
ACE Inhibitor
stent for renal hypertension |
| Stroke | platelet inhibitors |
| Vascular occlusion |
stents for aortic coarctation
platelet inhibitors |
Only affecting a small population by definition, rare diseases are a complex area for drug development, resulting in relatively few therapeutics on the market. Clinical trials need to be adapted for a smaller, dispersed and heterogenous sample, with clear-cut endpoint assessments. Artemida Pharma’s experience in this field through mucopolysaccharidosis syndromes allows us to build and implement bespoke strategies for these unique challenges.
| Rare Diseases Experience | Product Type |
|---|---|
|
Mucopolysaccharidosis Syndromes
MPS I
MPS II
MPS III
|
recombinant monoclonal antibody |